WuXi AppTec sinks 7.5% as HK biotech stocks extend sector rout

Hong Kong-listed pharmaceutical and biotech stocks tumbled on Tuesday, with WuXi AppTec leading the decline, as a sector-wide selloff deepened amid renewed US-China regulatory uncertainty and spillover from a global equity rout.

Hong Kong-listed pharmaceutical stocks suffered their worst session in months on Tuesday, with WuXi AppTec (02359.HK) plunging 7.5% to lead a sector-wide decline that erased billions in market value. WuXi Biologics (02269.HK) fell 4.5%, while Genscript Biotech (01548.HK) dropped 4.5%, tracking a broader selloff across Asia that has wiped out more than $2 trillion in regional equity value since Friday.

"The biotech selloff reflects a double hit — renewed fears over US legislation targeting Chinese contract research organizations, combined with the broader risk-off move triggered by the Iran-Israel escalation," said Kevin Ip, an equity strategist focused on Hong Kong markets. "WuXi names are particularly exposed given their heavy US revenue exposure."

The declines came as the Hang Seng Index slid 1.3%, extending losses from Monday when the benchmark fell alongside regional peers. The selloff was fueled by escalating military conflict between Israel and Iran over the weekend, which sent Brent crude above $94 a barrel, and lingering concerns that stronger-than-expected US jobs data will keep the Federal Reserve from cutting rates this year. The Shanghai Composite Index fell 1.7%, while South Korea's KOSPI plunged 8.3% — triggering a circuit breaker — and Japan's Nikkei 225 dropped 3.9%.

The pharmaceutical sector was the worst-performing group in Hong Kong on Tuesday, with the broader healthcare sub-index falling more than 4%. The selloff in WuXi AppTec alone erased roughly HK$15 billion in market capitalization. The stock has now lost more than 30% of its value since the start of the year, as the specter of the BIOSECURE Act — US legislation that would restrict federal contracts with certain Chinese biotech firms — has weighed on the sector.

Trading volumes across Hong Kong's healthcare sector surged to more than double the 20-day average, suggesting institutional selling pressure. The selloff also dragged down other contract development and manufacturing organizations, with Hangzhou Tigermed Consulting falling 3.2% and Pharmaron Beijing sliding 2.8%.

The broader market rout has been compounded by a sharp selloff in US tech stocks on Friday, when the S&P 500 fell 2.6% and the Nasdaq Composite slumped 4.2%, its worst session since April 2025. While Wall Street staged a partial recovery on Monday — the S&P 500 gained 0.3% and the Nasdaq rose 0.9% — the damage to risk appetite across Asia persisted into Tuesday's session.

The yuan weakened past 7.25 against the dollar, adding pressure on Chinese equities as a weaker currency raises the cost of dollar-denominated debt for Chinese companies. The yield on the US 10-year Treasury note edged up to 4.56%, extending its Friday jump, as traders priced in a higher-for-longer rate environment.

For WuXi AppTec and its peers, the next catalyst is the progress of the BIOSECURE Act through the US Congress, which could determine whether the sector faces permanent structural headwinds or a temporary valuation reset. The company's next earnings report, expected in August, will provide the first look at whether client attrition has accelerated.

This article is for informational purposes only and does not constitute investment advice.